Melina E. Marmarelis

Combined JAK inhibition and PD-1 immunotherapy for non–small cell lung cancer patients

Divij Mathew, Melina E. Marmarelis, Caitlin Foley et al. · Science · 2024 · 160 citations · Full text

Persistent Inflammation Refractory, Immunology, Immunologic Mechanism +19

CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors

Ferdinandos Skoulidis, Haniel A. Araújo, Minh Truong et al. · Nature · 2024 · 117 citations · Full text

Association of STK11/LKB1 genomic alterations with lack of benefit from the addition of pembrolizumab to platinum doublet chemotherapy in non-squamous non-small cell lung cancer.

Ferdinandos Skoulidis, Kathryn C. Arbour, Matthew D. Hellmann et al. · Journal of Clinical Oncology · 2019 · 99 citations

Immunology, Pathology, First-line Cpp +18

Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study

Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim et al. · Journal of Clinical Oncology · 2024 · 94 citations · Full text

Impact of <i>KRAS</i> and <i>TP53</i> Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With <i>STK11</i>-Mutated Advanced Non–Small-Cell Lung Cancer

Erin M. Bange, Melina E. Marmarelis, Wei‐Ting Hwang et al. · JCO Precision Oncology · 2019 · 70 citations